Brief: SynAct Pharma Q1 Sales SEK 0
31/05/2024 06:30
May 31 (Reuters) - SynAct Pharma Q1 cash flow from operating activities SEK -11.189 million. * Q1 adjusted EPS SEK -0.7 * Q1 net income SEK -24.906 million * Q1 operating expenses SEK 25.706 million
Recent news on SynAct Pharma AB
See all newsBrief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026